Obesity and Alzheimer’s disease: Molecular bases
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Obesity is a complex, chronic, and multifactorial condition characterized by abnormal fat accumulation in tissues and organs and inducing negative effects on human health. Alzheimer's disease is a progressive and irreversible neurodegenerative disease, associated with amyloid plaques and neurofibrillary tangles in the brain. The correlation between obesity and Alzheimer's disease has been discovered, but the molecules and molecular mechanisms linking these conditions are not yet fully elucidated. In this review, we focused on the most important processes linking the fat accumulation and the alterations of the brain structure and functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“AD pathogenesis (Nuzzo et al., 2014 and Nuzzo, Amato, et al., 2018; Nuzzo, Presti, et al., 2018, Pereira et al., 2019, Calsolaro & Edison, 2016).”
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611 · cited 1×
“Successively, Aβ interacts with neurons inducing cellular stress (Deane et al., 2003; Poljak et al., 2016).”
BackgroundThe blood-brain barrier in systemic inflammation
Varatharaj, A., & Galea, I. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.03.010 · Cited by 1,172 · cited 1×
“Over the past 20 years, various research groups have demonstrated the passage of cytokines through the BBB (Banks, Kastin, & Broadwell, 1995; Rochfort & Cummins, 2015; Varatharaj & Galea, 2017).”
BackgroundAnstey, K. J., Cherbuin, N., Budge, M., & Young, J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00825.x · Cited by 855
Passage of cytokines across the blood–brain barrier
Banks, W. A., Kastin, A. J., & Broadwell, R. D. (1996) · Neuroimmunomodulation · doi:10.1159/000097202 · Cited by 778
Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies
Gudala, K., Bansal, D., Schifano, F., & Bhansali, A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12087 · Cited by 727
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 1×
“Among these ones, we have to mention: (a) hyperinsulinemia, leading to the competition between insulin-degrading enzyme (IDE) and Aβ with reduction of the Aβ brain clearance; (b) binding of Aβ oligomers to the insulin receptors, causing impairment of the insulin signaling pathways; and (c) downregulation and internali…”
BackgroundNguyen, D. M., & El-Serag, H. B. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.014 · Cited by 531 · cited 1×
“Obesity and being overweight are essentially caused by an energy imbalance between consumed and burned calories and are determined by an interplay of environmental factors, genetic predisposition, and behavior (Nguyen & El-Serag, 2010).”
BackgroundClaxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., & Craft, S. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141791 · Cited by 467
Starr, J. M. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.1.70 · Cited by 434 · cited 1×
“Indeed, the peripheral insulin resistance or high insulin levels reduce the level of insulin transporters and decrease the BBB permeability to insulin (Arnold et al., 2014; Starr et al., 2003).”
BackgroundReview: Systemic inflammation andAlzheimer's disease
Holmes, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01307.x · Cited by 356 · cited 2×
“Many results suggest an important role of the systemic inflammation in the pathogenesis of Alzheimer's disease (Holmes, 2013).”
BackgroundCholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335 · cited 1×
“Recently, in adults with mild cognitive impairment or AD, the regular insulin treatment was also associated with brain preserved volume as demonstrated by magnetic resonance images and reduction in the tau-P181/Aβ42 ratio (Craft et al., 2017).”
Backgroundde la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Kim, D.-G., Krenz, A., Toussaint, L. E., Maurer, K. J., Robinson, S.-A., Yan, A., Torres, L., & Bynoe, M. S. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0467-5 · Cited by 330 · cited 1×
“Different studies show that non-alcoholic fatty liver disease (NAFLD) induced by HFD promotes AD in mice (Kim et al., 2016; Nuzzo, Presti, et al., 2018) through different mechanisms.”
BackgroundKanekiyo, T., & Bu, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00093 · Cited by 281
Puig, K. L., Floden, A. M., Adhikari, R., Golovko, M. Y., & Combs, C. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030378 · Cited by 152
Nose-to-brain delivery of insulin enhanced by a nanogel carrier
Picone, P., Sabatino, M. A., Ditta, L. A., Amato, A., San Biagio, P. L., Mulè, F., Giacomazza, D., Dispenza, C., & Di Carlo, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.040 · Cited by 148 · cited 1×
“Furthermore, the nasal administration of the same insulin-nanogel system in C57BL/6J mouse revealed an improvement of the brain insulin delivery demonstrating that it can be an alternative route for the treatment of the AD, thus avoiding unpleasant systemic effects (Picone et al., 2018).”
BackgroundSelf-citationInsulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer‘s Disease
Nuzzo, D., Picone, P., Baldassano, S., Caruana, L., Messina, E., Gammazza, A., Cappello, F., Mulè, F., & Carlo, M. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150710115506 · Cited by 119 · cited 1×
“In humans and in animal models, numerous data suggest that consumption of HFD can lead to memory deficits and significant brain inflammation and oxidative stress (Nuzzo et al., 2015, 2019, and 2020; Guillemot-Legris & Muccioli, 2017).”
BackgroundCholesterol in Alzheimer’s Disease and other Amyloidogenic Disorders
Harris, J. R., & Milton, N. G. N. (2010) · Subcellular Biochemistry · doi:10.1007/978-90-481-8622-8_2 · Cited by 44 · cited 1×
“Different experiments strongly suggest that cholesterol has an elevated affinity for APP and Aβ (Harris & Milton, 2010).”
Background
Cited by
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
Shabbir, U., Arshad, M. S., Sameen, A., & Oh, D.-H. (2021) · Nutrients · doi:10.3390/nu13020690 · Cited by 191
Glaesser, D., & Iwig, M. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109888 · Cited by 9
Metadata
- Authors
- Picone, P., Di Carlo, M., & Nuzzo, D.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2020-05-23
- Volume
- 52
- Issue
- 8
- Pages
- 3944-3950
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W3018155034
- Cited by
- 76
- References
- 23
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.